ClinicalTrials.gg
CompletedNCT07286526Updated Oct 27, 2026Results posted

Comparison of Bolus and Continuous Hydration Regimens for the Prevention of Contrast-Associated Acute Kidney Injury in the Emergency Department

A Phase 4 interventional study of Bolus hydration therapy and Continuous hydration therapy in Acute Kidney Injury Following Administration of Contrast Media, sponsored by Yunus Emre Gemici. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Yunus Emre Gemici · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2024, registered Dec 2025).
Updated Oct 27, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.

Enrollment
2nd of 17
285 · median 108
Started
2024
with 12 others
Phase 4
3 of 90
none open now
Registered
61st of 90
by date

Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 13 that started in 2024, is one of 3 in phase 4, and was the 61st registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Acute Kidney Injury with a site in Turkey, or all of them as a file.
02

Study summary

A single-center, prospective, open-label, non-inferiority randomized controlled clinical trial was conducted at the ED of a tertiary hospital. The ED staff consisted of a mix of emergency medicine specialists, emergency medicine residents, and general practitioners.

Between August 10, 2024, and March 26, 2025, patients aged 18 and over who presented to the ED with creatinine levels above the reference range (1.2 mg/dl in men and 1.1 mg/dl in women) and underwent contrast-enhanced tomography were deemed eligible for inclusion in the study.

Eligible patients were randomly allocated in a 1:1 ratio to receive either bolus hydration or continuous hydration therapy. Permuted block randomization was employed at each participating site to distribute patients, stratified by age groups (18-44, 45-59, 60-74, and 75 years and older) and gender. This study did not use blinding. Both the implementers of the intervention and the researchers evaluating the outcome measures are aware of the intervention groups.

After the patients were divided into two groups, one group received bolus hydration therapy while the other group received continuous hydration therapy.

According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol.

The IV contrast agent used in the study was iohexol, which belongs to the non-ionic low osmolar contrast agent group. 300 mgI/ml 100 ml solutions were used, and the dose was adjusted between 80 and 100 ml depending on the imaging and the patient. In the majority of patients, 100 ml of contrast was administered, with an average of 98 ml of solution given in the bolus hydration group and an average of 96 ml of solution given in the continuous hydration group.

Patients were given control forms to provide follow-up blood samples 48-72 hours later and were asked to present to the ED with the form on the specified date. To inquire about the development of dialysis needs and mortality status, patients were contacted 30 days later to gather information.

03

Conditions studied

  • Acute Kidney Injury Following Administration of Contrast Media

Browse trials for

Keywords

  • non-inferiorty
  • randomized controlled trial
  • contrast associated acute kidney injury
  • contrast agents
  • hydration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presented to the Emergency Department creatinine levels above the reference range (1.2 mg/dl in men and 1.1 mg/dl in women)
  • Underwent contrast-enhanced tomography

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Known allergy history to contrast agents
  • Exposure to contrast agents within the last 72 hours
  • Being on dialysis due to end-stage kidney disease
  • Presenting with decompensated heart failure
  • Patients who were unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Bolus hydration therapy

    In the Bolus hydration therapy group, 500 ml of 0.9% saline treatment was started half an hour before the procedure and after the procedure, 1000 ml of 0.9% saline treatment was continued at a rate of 500 ml/h to be completed in 2 hours. A total of 1500 ml 0.9% saline hydration therapy was administered over 2.5 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the bolus hydration group, 250 ml of treatment was administered half an hour before the procedure, and hydration was continued at a rate of 250 ml/h for 2 hours after the procedure.

    Drug: Bolus hydration therapy

  • Active comparator
    Continuous hydration therapy

    In the Continuous hydration therapy group, saline treatment started 2 hours before the intravenous (IV) contrast agent application at a rate of 150 ml/h, and hydration was applied for 8 more hours after the procedure at the same rate. A total of 1500 ml 0.9% saline hydration therapy was administered over 10 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the continuous hydration group, 75 ml/h of hydration was administered for 2 hours before the procedure and for 8 hours after the procedure.

    Drug: Continuous hydration therapy

Interventions

  • DrugBolus hydration therapy

    In the Bolus hydration therapy group, 500 ml of 0.9% saline treatment was started half an hour before the procedure and after the procedure, 1000 ml of 0.9% saline treatment was continued at a rate of 500 ml/h to be completed in 2 hours. A total of 1500 ml 0.9% saline hydration therapy was administered over 2.5 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the bolus hydration group, 250 ml of treatment was administered half an hour before the procedure, and hydration was continued at a rate of 250 ml/h for 2 hours after the procedure.

  • DrugContinuous hydration therapy

    In the Continuous hydration therapy group, saline treatment started 2 hours before the intravenous (IV) contrast agent application at a rate of 150 ml/h, and hydration was applied for 8 more hours after the procedure at the same rate. A total of 1500 ml 0.9% saline hydration therapy was administered over 10 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the continuous hydration group, 75 ml/h of hydration was administered for 2 hours before the procedure and for 8 hours after the procedure.

06

What researchers measure

Primary outcomes

  1. Rate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)

    The primary outcome of our study was the development of CA-AKI, defined as an increase in serum creatinine value by ≥25% compared to baseline or an absolute increase in serum creatinine value by ≥0.5 mg/dL within 48-72 hours after contrast administration.

    Time frame: 48-72 hours after contrast administration

Secondary outcomes

  1. Rate of Participants Who Required Dialysis

    Patients were contacted by phone 1 month after the procedure and asked about the development of dialysis needs within that 1-month period.

    Time frame: Up to 1 month after contrast administration

  2. All-Cause Mortality Rate

    Patients were contacted by phone 1 month after the procedure and asked about the all-cause Mortality within that 1-month period.

    Time frame: Up to 1 month after contrast administration

07

Results

Posted Oct 27, 2026
Limitations and caveats
This single-center study limits generalizability. Patients admitted to the ward or ICU may have received additional hydration during follow-up, and post-discharge treatments could not be monitored. Hydration was administered in ml/hr rather than the ml/kg/hr used in the literature, limiting standardization. Blinding was not feasible due to the nature of the intervention.

Participant flow

Between August 10, 2024, and March 26, 2025, patients aged 18 and over who presented to the ED with creatinine levels above the reference range (1.2 mg/dl in men and 1.1 mg/dl in women) and underwent contrast-enhanced tomography were deemed eligible for inclusion in the study.

Participant flow — Overall Study
MilestoneBolus Hydration TherapyContinuous Hydration Therapy
Started143142
Completed122115
Not completed2127

Outcome measures

PrimaryRate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)

The primary outcome of our study was the development of CA-AKI, defined as an increase in serum creatinine value by ≥25% compared to baseline or an absolute increase in serum creatinine value by ≥0.5 mg/dL within 48-72 hours after contrast administration.

Time frame:
48-72 hours after contrast administration
Reported as:
Count of participants · Participants
Rate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)
ParticipantsBolus Hydration TherapyContinuous Hydration Therapy
Rate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)62
SecondaryRate of Participants Who Required Dialysis

Patients were contacted by phone 1 month after the procedure and asked about the development of dialysis needs within that 1-month period.

Time frame:
Up to 1 month after contrast administration
Reported as:
Count of participants · Participants
Rate of Participants Who Required Dialysis
ParticipantsBolus Hydration TherapyContinuous Hydration Therapy
Rate of Participants Who Required Dialysis00
SecondaryAll-Cause Mortality Rate

Patients were contacted by phone 1 month after the procedure and asked about the all-cause Mortality within that 1-month period.

Time frame:
Up to 1 month after contrast administration
Reported as:
Count of participants · Participants
All-Cause Mortality Rate
ParticipantsBolus Hydration TherapyContinuous Hydration Therapy
All-Cause Mortality Rate1010

Adverse events

Collected over Adverse events were monitored throughout the one-month follow-up period after the enrollment of the patients.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bolus Hydration Therapy10/131 (7.6%)0/131 (0%)2/131 (1.5%)
Continuous Hydration Therapy10/126 (7.9%)0/126 (0%)1/126 (0.8%)
Most frequent other events
Most frequent other events
EventBolus Hydration TherapyContinuous Hydration Therapy
Contrast agent allergySkin and subcutaneous tissue disorders2/1311/126

Baseline characteristics

Age, Continuous
Age, Continuous(year)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Median72 (60 to 80)73 (61 to 79)73 (60 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Female6059119
Male7167138
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Turkey131126257
Clinical characteristics
Clinical characteristics(Participants)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Diabetes Mellitus5564119
Hypertension8587172
Heart Failure192342
Coronary Artery Disease423375
Stroke History121123
Biochemical characteristics (Creatinine, urea, glucose)
Biochemical characteristics (Creatinine, urea, glucose)(mg/dl)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Creatinine1.36 (1.25 to 1.52)1.32 (1.24 to 1.48)1.34 (1.25 to 1.5)
Urea58.5 (45.4 to 77.3)58.7 (44.5 to 72.7)58.5 (45 to 75.5)
Glucose136 (109 to 180)139.5 (115 to 188)137 (114 to 182)
Biochemical characteristics (eGFR)
Biochemical characteristics (eGFR)(mL/min/1.73 m²)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Median45.3 (37.5 to 51.7)45.6 (39.8 to 53)45.3 (38.8 to 52.3)
Biochemical characteristics (Hemoglobin)
Biochemical characteristics (Hemoglobin)(g/l)Bolus Hydration TherapyContinuous Hydration TherapyTotal
Median125 (110 to 142)132 (115 to 142)128 (111 to 142)

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Gaziosmanpaşa Training and Research Hospital
    Istanbul, 34255, Turkey (Türkiye)
09

References and documents

Publications

  • Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010 Jul;256(1):21-8. doi: 10.1148/radiol.10092000. No abstract available. PubMed 20574082 ↗
  • James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013 Feb;6(1):37-43. doi: 10.1161/CIRCINTERVENTIONS.112.974493. Epub 2013 Jan 15. PubMed 23322741 ↗
  • Cho E, Ko GJ. The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy. Diagnostics (Basel). 2022 Jan 12;12(1):180. doi: 10.3390/diagnostics12010180. PubMed 35054347 ↗
  • Ehmann MR, Klein EY, Zhao X, Mitchell J, Menez S, Smith A, Levin S, Hinson JS. Epidemiology and Clinical Outcomes of Community-Acquired Acute Kidney Injury in the Emergency Department: A Multisite Retrospective Cohort Study. Am J Kidney Dis. 2024 Jun;83(6):762-771.e1. doi: 10.1053/j.ajkd.2023.10.009. Epub 2023 Dec 10. PubMed 38072210 ↗
  • Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6;124(23):e574-651. doi: 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. No abstract available. PubMed 22064601 ↗
  • Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. PubMed 30165437 ↗
  • Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982 Dec;3(4):345-53. doi: 10.1016/0197-2456(82)90024-1. PubMed 7160191 ↗
  • Sebastia C, Paez-Carpio A, Guillen E, Pano B, Garcia-Cinca D, Poch E, Oleaga L, Nicolau C. Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study). Eur J Radiol. 2021 Mar;136:109509. doi: 10.1016/j.ejrad.2020.109509. Epub 2021 Jan 14. PubMed 33516141 ↗
  • Lombardi M, Molisana M, Genovesi E, De Innocentiis C, Limbruno U, Misuraca L, Moretti L, Di Vito L, Renda G, Zimarino M, Di Nicola M, De Caterina R. Urine alkalinisation to prevent contrast-induced acute kidney injury: the prospective, randomised, controlled, open-label TEATE trial. EuroIntervention. 2022 Sep 20;18(7):562-573. doi: 10.4244/EIJ-D-22-00010. PubMed 35620986 ↗
  • Ravn EJ, Hasific S, Thomassen M, Hjortebjerg R, Bach Laursen K, Diederichsen A, Bistrup C, Ovrehus KA. Intravenous versus oral hydration to reduce the risk of postcontrast acute kidney injury after intravenous contrast-enhanced CT in patients with severe chronic kidney disease (ENRICH): a study protocol for a single-centre, parallel-group, open-labelled non-inferiority randomised controlled trial in Denmark. BMJ Open. 2023 Sep 12;13(9):e074057. doi: 10.1136/bmjopen-2023-074057. PubMed 37699636 ↗
  • Somkereki C, Palfi R, Scridon A. Prevention of contrast-associated acute kidney injury in an era of increasingly complex interventional procedures. Front Med (Lausanne). 2024 Jan 9;10:1180861. doi: 10.3389/fmed.2023.1180861. eCollection 2023. PubMed 38264052 ↗
  • Section 4: Contrast-induced AKI. Kidney Int Suppl (2011). 2012 Mar;2(1):69-88. doi: 10.1038/kisup.2011.34. No abstract available. PubMed 25018920 ↗
  • Li Y, Wang J. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrol. 2024 Apr 22;25(1):140. doi: 10.1186/s12882-024-03570-6. PubMed 38649939 ↗
  • Arslan S, Yildiz A, Dalgic Y, Batit S, Kilicarslan O, Ser OS, Dalgic SN, Kocas C, Abaci O. Avoiding the emergence of contrast-induced acute kidney injury in acute coronary syndrome: routine hydration treatment. Coron Artery Dis. 2021 Aug 1;32(5):397-402. doi: 10.1097/MCA.0000000000000966. PubMed 33060531 ↗
  • Liu Y, Tan N, Huo Y, Chen S, Liu J, Chen YD, Wu K, Wu G, Chen K, Ye J, Liang Y, Feng X, Dong S, Wu Q, Ye X, Zeng H, Zhang M, Dai M, Duan CY, Sun G, He Y, Song F, Guo Z, Chen PY, Ge J, Xian Y, Chen J. Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial. Heart. 2022 May 25;108(12):948-955. doi: 10.1136/heartjnl-2021-319716. PubMed 34509996 ↗
  • Liu Y, Tan N, Huo Y, Chen SQ, Liu J, Wang Y, Li L, Tao JH, Su X, Zhang L, Li QX, Zhang JY, Guo YS, Du ZM, Zhou YP, Fang ZF, Xu GM, Liang Y, Tao L, Chen H, Ji Z, Han B, Chen PY, Ge JB, Han YL, Chen JY. Simplified Rapid Hydration Prevents Contrast-Associated Acute Kidney Injury Among CKD Patients Undergoing Coronary Angiography. JACC Cardiovasc Interv. 2023 Jun 26;16(12):1503-1513. doi: 10.1016/j.jcin.2023.03.025. PubMed 37380233 ↗
  • Chen F, Lu J, Yang X, Liu D, Wang Q, Geng X, Xiao B, Zhang J, Liu F, Gu G, Cui W. Different hydration methods for the prevention of contrast-induced nephropathy in patients with elective percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2023 Jun 24;23(1):323. doi: 10.1186/s12872-023-03358-w. PubMed 37355592 ↗
  • Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerda J, Chawla LS. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018 Oct;14(10):607-625. doi: 10.1038/s41581-018-0052-0. PubMed 30135570 ↗
  • Batte A, Shahrin L, Claure-Del Granado R, Luyckx VA, Conroy AL. Infections and Acute Kidney Injury: A Global Perspective. Semin Nephrol. 2023 Sep;43(5):151466. doi: 10.1016/j.semnephrol.2023.151466. Epub 2023 Dec 28. PubMed 38158245 ↗
  • Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021 Jul 15;7(1):52. doi: 10.1038/s41572-021-00284-z. PubMed 34267223 ↗
  • Section 1: Introduction and Methodology. Kidney Int Suppl (2011). 2012 Mar;2(1):13-18. doi: 10.1038/kisup.2011.31. No abstract available. PubMed 25018917 ↗
  • Gemici YE, Ay F, Cimen AG, Sarbay I, Calik M. Comparison of Bolus and Continuous Hydration Regimens for the Prevention of Contrast-Associated Acute Kidney Injury in the Emergency Department: A Randomized Controlled Noninferiority Trial. Emerg Med Int. 2026 Jul 30;2026:8497484. doi: 10.1155/emmi/8497484. eCollection 2026. PubMed 42539856 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves single-center clinical data without a dedicated data-sharing infrastructure, and sharing these data may pose risks to participant privacy despite de-identification efforts.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Mar 2025, 7 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's 7 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 16, 2025
StartActual
Aug 10, 2024
Primary completionActual
Mar 29, 2025
CompletionActual
Apr 26, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameRate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)From enrollment to the end of treatment at 1 week → 48-72 hours after contrast administration
Oct 27, 2026
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameRate of Participants Who Required DialysisFrom enrollment to the end of treatment at 1 month → Up to 1 month after contrast administration
  • Time frameAll-Cause Mortality RateFrom enrollment to the end of treatment at 1 month → Up to 1 month after contrast administration
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameRate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)From enrollment to the end of treatment at 1 week → 48-72 hours after contrast administration
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameRate of Participants Who Required DialysisFrom enrollment to the end of treatment at 1 month → Up to 1 month after contrast administration
    • Time frameAll-Cause Mortality RateFrom enrollment to the end of treatment at 1 month → Up to 1 month after contrast administration
    + 3 other changes: registry notes, index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07286526
Lead sponsor
Yunus Emre Gemici
Responsible party
Yunus Emre Gemici (MD, Gaziosmanpasa Research and Education Hospital) — Sponsor-investigator
First posted
Dec 16, 2025
Start date
Aug 10, 2024
Primary completion
Mar 29, 2025
Completion
Apr 26, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Mustafa Çalık, MD, Assoc. Prof.
study director · Department of Emergency Medicine Gaziosmanpaşa Training and Research Hospital, İstanbul, Türkiye

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion